Relevant bibliographies by topics / Venous thrombosis

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Venous thrombosis'

Author: Grafiati
Published: 4 June 2021
Last updated: 28 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Venous thrombosis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Venous thrombosis"

1

Sands, Jeffrey J., and Carol L. Miranda. "State-of-the-Art Review : Treatment of Hemodialysis Access Failure: A Role for Thrombolysis." Clinical and Applied Thrombosis/Hemostasis 2, no. 3 (July 1996): 164–68. http://dx.doi.org/10.1177/107602969600200304.

Full text
Abstract:
Thrombosis of hemodialysis accesses remains a major source of morbidity, hospitalization, and expense for patients with end-stage renal disease. Treatment of hemodialysis accesses includes strategies to prevent ac cess failure and methods for treating acute thromboses. Such techniques as Doppler ultrasonography, venous pressure monitoring during dialysis, measurement of ra tios of venous to systemic pressures, and measurement of recirculation have been used to predict accesses at risk of thrombosis. Elective interventions, including surgical re visions and angioplasties, have been shown to lessen the thrombosis rate in both polytetrafluoroethylene (PTFE) grafts and arterio-venous fistulas. Elective revision has also improved long-term patency of both grafts and fistu las when compared with repairing the accesses only after thrombosis. Despite these attempts, acute thrombosis of hemodialysis accesses remains a common complication for patients with end-stage renal disease. Historically, surgical thrombectomy has been the gold standard for treatment of acute hemodialysis access failure. Over the past 10 years, thrombolytic therapy has gained an in creasing role in the treatment of acutely thrombosed PTFE grafts. Thrombolysis has had at least comparable results to surgical thrombectomy in the best centers, with similar complication rates. Thrombolytic therapy is also significantly less expensive than surgical thrombectomy. In summary, we believe that hemodialysis access treat ment should encompass a comprehensive program, in cluding access surveillance to select accesses at risk of failure. Elective intervention should be performed in an attempt to prevent thrombosis and increase long-term ac cess patency. When thrombosis does occur, pharmaco mechanical thrombolysis is the preferable first interven tion for acutely occluded PTFE hemodialysis accesses.
APA, Harvard, Vancouver, ISO, and other styles
2

Palazzo, Paola, Pierre Agius, Pierre Ingrand, Jonathan Ciron, Matthias Lamy, Aline Berthomet, Paul Cantagrel, and Jean-Philippe Neau. "Venous Thrombotic Recurrence After Cerebral Venous Thrombosis." Stroke 48, no. 2 (February 2017): 321–26. http://dx.doi.org/10.1161/strokeaha.116.015294.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rana, K. G. S., A. Jhamb, Mukul Verma, and Harsh Rastogi. "Thrombolysis for Cerebral Venous Thrombosis." Apollo Medicine 4, no. 1 (March 2007): 69–71. http://dx.doi.org/10.1016/s0976-0016(11)60439-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Comerota, Anthony J. "Thrombolysis for deep venous thrombosis." Journal of Vascular Surgery 55, no. 2 (February 2012): 607–11. http://dx.doi.org/10.1016/j.jvs.2011.06.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Renowden, Shelley. "Cerebral venous thrombosis: Local thrombolysis." Journal of the Royal Society of Medicine 93, no. 5 (May 2000): 241–43. http://dx.doi.org/10.1177/014107680009300507.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pilger, E., M. Decrinis, A. Obernosterer, and G. Stark. "Thrombolysis in deep venous thrombosis." Vascular Medicine Review vmr-1, no. 2 (September 1990): 167–78. http://dx.doi.org/10.1177/1358836x9000100206.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rana, K. G. S., A. Jhamb, Mukul Verma, and Harsh Rastogi. "Thrombolysis for Cerebral Venous Thrombosis." Apollo Medicine 4, no. 1 (March 2007): 69–71. http://dx.doi.org/10.1177/0976001620070114.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Heidrich, Konau, and Hesse. "Asymptomatic venous thrombosis in cancer patients – a problem often overlooked. Results of a retrospective and prospective study." Vasa 38, no. 2 (May 1, 2009): 160–66. http://dx.doi.org/10.1024/0301-1526.38.2.160.

Full text
Abstract:
Background: Venous thrombosis with and without pulmonary embolism is a frequent complication of malignancies and second among the causes of death in tumour patients. Its incidence is reported to be 10 to 15%. Since for methodological reasons, this rate can be assumed to be too low and to disregard asymptomatic venous thrombosis, a combined retrospective and prospective study was performed to examine the actual frequency of venous thrombosis in tumour patients. Patients and methods: The histories of 409 patients (175 women, 234 men, mean age 69 years [19 to 96 years]) with different tumours, consecutively enrolled in the order of their altogether 426 inpatient treatments, were checked in retrospect for the frequency of venous thrombosis and pulmonary embolism. Subsequently, 97 tumour inpatients (36 women, 61 men, mean age 70 years [42 to 90 years]) were systematically screened, by means of duplex sonography and/or venography, for venous thromboses in the veins of the pelvis and both legs. Results: In the retrospective analysis, where no systematic screening for thromboses was performed and only symptomatic thrombosis was recorded, venous thrombosis was found in 6.6% of all tumour patients, whereas in the prospective examination with systematic duplex sonography and / or venography of all patients, the percentage was 33%. In the prospective study, 31.3% of venous thromboses were symptomatic and 68.7% asymptomatic. In 39.3% of the cases in the retrospective analysis and 25% in the prospective analysis, venous thrombosis occurred during chemotherapy, surgery or radiation therapy. Venous thrombosis was most often seen in metastasizing tumours and in colorectal carcinoma (40%), haematological system diseases (28.6%), gastric cancer (30%), bronchial, pancreas and ovarian carcinoma (28.6%), and carcinoma of the prostate (16.7%). Conclusion: Regular screening for thrombosis is indicated even in asymptomatic tumour patients because asymptomatic venous thrombosis is frequent, can lead to pulmonary embolism and has to be treated like symptomatic venous thrombosis. This is particularly true for metastasization during chemotherapy, surgical interventions, or radiation.
APA, Harvard, Vancouver, ISO, and other styles
9

Mouton, Zehnder, Wagner, and Mouton. "Follow-up after deep venous thrombosis in azygos continuation." Vasa 34, no. 4 (November 1, 2005): 266–68. http://dx.doi.org/10.1024/0301-1526.34.4.266.

Full text
Abstract:
Background: To determine the sequelae of patients after deep venous thrombosis in patients with azygos continuation defined as agenesis of the inferior vena cava with collateral flow. Patients and methods: Five patients post deep venous thrombosis in the context of azygos continuation were followed up clinically and with colour duplex ultrasonography. Results: All five patients had to our knowledge after the initial deep venous thrombosis no further thromboembolic events. Three patients after isolated iliac thromboses are symptom free or nearly symptom free, two after more extended thromboses still suffer from venous claudication. Four patients are without anticoagulation, one patient is permanently orally anticoagulated. Conclusions: Azygos continuation may not influence the risk of recurrent venous thrombo-embolism nor the outcome of a deep venous thrombosis. Careful deep venous thrombosis prophylaxis in patients with azygos continuation may be sufficient when a risk factor is present but conclusions lack due to the small numbers of patients of enough supportive data.
APA, Harvard, Vancouver, ISO, and other styles
10

Stefano, Valerio De, and Ida Martinelli. "Rare thromboses of cerebral, splanchnic and upper-extremity veins." Thrombosis and Haemostasis 103, no. 06 (2010): 1136–44. http://dx.doi.org/10.1160/th09-12-0873.

Full text
Abstract:
SummaryVenous thrombosis typically involves the lower extremity circulation. Rarely, it can occur in the cerebral or splanchnic veins and these are the most frightening manifestations because of their high mortality rate. A third site of rare venous thrombosis is the deep system of the upper extremities that, as for the lower extremity, can be complicated by pulmonary embolism and post-thrombotic syndrome. The authors conducted a narrative review focused on clinical manifestations, risk factors, and treatment of rare venous thromboses. Local risk factors such as infections or cancer are frequent in thrombosis of cerebral or portal veins. Upper extremity deep-vein thrombosis is mostly due to local risk factors (catheter- or effort-related). Common systemic risk factors for rare venous thromboses are inherited thrombophilia and oral contraceptive use; chronic myeloproliferative neoplasms are closely associated with splanchnic vein thrombosis. In the acute phase rare venous thromboses should be treated conventionally with low-molecular-weight heparin. Use of local or systemic fibrinolysis should be considered in the case of clinical deterioration in spite of adequate anticoagulation. Anticoagulation with vitamin K-antagonists is recommended for 3–6 months after a first episode of rare venous thrombosis. Indefinite anticoagulation is recommended for Budd-Chiari syndrome, recurrent thrombosis or unprovoked thrombosis and permanent risk factors. In conclusion, the progresses made in the last couple of decades in diagnostic imaging and the broadened knowledge of thrombophilic abnormalities improved the recognition of rare venous thromboses and the understanding of pathogenic mechanisms. However, the recommendations for treatment mainly derive from observational studies.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Venous thrombosis"

1

Brown, John Gordon. "A study of deep venous thrombosis." Thesis, Queen's University Belfast, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.303015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Payne, Holly. "Novel insights into the mechanisms of venous thrombosis." Thesis, University of Birmingham, 2018. http://etheses.bham.ac.uk//id/eprint/8172/.

Full text
Abstract:
Venous thrombosis is a major health concern, with an annual incidence of ~1 per 1000 adults (Cushman 2007). This includes deep vein thrombosis (DVT) and pulmonary embolism (PE), the fatal consequence of a clot detaching and moving to the lungs, together these diseases are termed venous thromboembolism (VTE). Current treatment options for VTE are often associated with serious side effects and bleeding complications, highlighting the need for more effective prophylaxis. This study therefore aimed to identify new targets to treat DVT, which would not have the associated negative side effects. This study shows the platelet receptor CLEC-2 (C-type lectin receptor 2) plays an important role in DVT, probably through interaction with podoplanin in the IVC wall, and that lack of CLEC-2 is protective in this disease. We show other immune cells may also play a role in DVT, and demonstrate that mast cell deficiency is protective in vivo. Furthermore, we suggest that the mast cell constituent responsible for the prothrombotic phenotype is likely to be histamine. Preliminary data also suggests that T-cells may have a protective role in DVT, and that thrombin may be important for the release of neutrophil extracellular traps (NETs) from neutrophils inside a growing thrombus.
APA, Harvard, Vancouver, ISO, and other styles
3

Lindmarker, Per. "Treatment of deep vein thrombosis and risk of recurrent venous thromboembolism /." Stockholm, 1998. http://diss.kib.ki.se/1998/91-628-3211-5/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Robins, Richard. "The role of vascular Gas6 in the pathophysiology of Venous Thrombosis." Thesis, McGill University, 2013. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=114250.

Full text
Abstract:
Gas6 is a vitamin K-dependent, secreted protein that amplifies platelet aggregation and secretion in response to platelet agonists. Gas6-/- mice are protected from experimentally induced lethal venous and arterial thromboembolism. This protection has been attributed to defective aggregation in platelets from Gas6-/- mice. However, this platelet phenotype was only observed when platelets were challenged by one agonist, ADP, and only at a concentration of 5.0 µM. This subtle platelet abnormality resulting in a rather dramatic clinical phenotype raises the possibility that Gas6 from a source other than platelets contributes to thrombus formation. We hypothesize that Gas6 derived from the vasculature plays a role in venous thrombus formation. Gas6-/- mice are protected against venous thrombosis induced by 0.37 M FeCl3 in the inferior vena cava (IVC). Bone marrow transplantation experiments generating mice with selective ablations of Gas6 from either the hematopoietic or vascular compartments demonstrate an approximately equal contribution by Gas6 from both compartments to thrombus formation. Platelet depletion in wild type or Gas6-/- mice followed by reconstitution with platelets from either WT or Gas6-/- mice confirm that Gas6 from compartments other than the platelet contribute to thrombosis development. Furthermore, Gas6-/- mice are hyporesponsive to FeCl3 mediated tissue factor induction in venous endothelium, as observed by immunofluorescence micoscopy and further validated by a functional assay. In addition, in vitro, Gas6-/- endothelial cells are hyporesponsive to thrombin mediated tissue factor mRNA induction. Taken together, these results suggest that vascular derived Gas6 contributes to thrombus formation in vivo and can partially be explained by the ability of Gas6 to promote endothelial tissue factor induction. We also begin to explore the involvement of the FOX family transcription factor FoxO1 as a downstream mediator of Gas6 induced expression of VCAM-1 during endothelial activation. These findings support the notion that vascular Gas6 may play a pathophysiologic role in venous thromboembolism
Gas6 est une protéine vitamine-K dépendante, sécrétée qui contribue à l'agrégation des plaquettes. Les souris déficientes en Gas6 (Gas6-/-) sont protégées contre les thromboses artérielles et veineuses. La résistance à la thromboses des souris déficientes en Gas6 était attribuée à une réponse plaquettaire défectueuse. Cependant, la phénotype plaquettaire était observée uniquement avec le traitement des plaquettes avec une concentration faible de l'ADP (5.0µM). Cette observation indique la possibilité d'une contribution de Gas6 d'une source distincte des plaquettes. Nous faisons l'hypothèse que Gas6 dérivé d'une source vasculaire contribue à la formation d'une thrombus. Les souris Gas6-/- sont protégées contre la formation des thromboses dans la veine cave inférieure induite par 0.37 M FeCl3. En utilisant des greffes de moelle osseuse, nous avons généré des souris avec les déficits de Gas6 soit dans le compartiment vasculaire ou hématopoïétique. La formation des thromboses dans les souris chimériques était intermédiaire entre les deux groupes contrôles. L'épuisement des plaquettes dans les souris WT, suivi de la reconstitution avec des plaquettes Gas6-/- a confirmé les résultats obtenus par les greffes de moelle osseuse. En outre, l'induction du facteur tissulaire était atténuée dans les cellules vasculaires des souris Gas6-/-. Additionellement, in vitro, les cellules endothéliales étaient aussi hypo réactives en ce qui concerne l'induction du facteur tissulaire. Nos résultats suggèrent que Gas6 dérivé d'une source vasculaire contribue à la formation in vivo d'une thrombose, en partie dû a l'induction du facteur tissulaire. Nous avons commencé à examiner l'hypothèse à savoir si la protéine FoxO1 est impliquée dans l'induction de VCAM-1 parmi les cascades de signalisation de Gas6. Donc, en guise de conclusion nos résultats soutiennent l'idée que Gas6 vasculaire peut jouer un rôle physiopathologique dans la thrombose veineuse.
APA, Harvard, Vancouver, ISO, and other styles
5

Dai, Guohao 1970. "Computational and biological studies of mechanical prophylaxis against deep venous thrombosis." Thesis, Massachusetts Institute of Technology, 2001. http://hdl.handle.net/1721.1/28236.

Full text
Abstract:
Thesis (Ph. D.)--Harvard--Massachusetts Institute of Technology Division of Health Sciences and Technology, 2001.
Includes bibliographical references (p. 137-151).
Deep vein thrombosis (DVT) of the lower extremity and induced pulmonary embolism are common complications resulting from prolonged periods of bed-rest or immobilization of the limbs. One of the most effective methods of prophylaxis against DVT is external pneumatic compression (EPC). In spite of its wide acceptance as an effective means of prophylaxis, its mechanism remains poorly understood and optimal compression conditions have not been defined. Understanding the biological consequences of EPC is an important goal for optimizing the performance of compression device and providing guidance for clinical use. In the first part of this thesis, a computational model of the leg was developed to simulate hemodynamic conditions under EPC and the influence of different modes of compression were analyzed and compared. Then, a new in vitro cell culture system was developed that can be used to examine the effect of hemodynamic conditions during EPC on endothelial cell (EC) function. The biologic response was assessed through changes in cell morphology and the expression of various pro-thrombotic and anti-thrombotic factors related to EC.
(cont.) The results show that intermittent flow associated with EPC up-regulates EC fibrinolytic potential and vasomotor function. Using DNA microarray technology, the data of thrombo-regulatory factors indicates that EC gene expression shifts toward anti-thrombotic vs. pro-thrombotic under EPC. Finally, Nitric Oxide (NO), an important regulator of vasomotor and platelet functions was studied in detail under various cycles of EPC. The results show that NO production and eNOS mRNA respond differentially to modes of EPC. Further exploration using the system can potentially reveal the optimum combination of forces to better regulate thromboresistant effects desired for DVT prophylaxis.
by Guohao Dai.
Ph.D.
APA, Harvard, Vancouver, ISO, and other styles
6

Wilson, Stanley Darrin. "An investigation of lower limb venous function, whole blood coagulation and deep venous thrombosis following proximal femoral fracture." Thesis, Queen's University Belfast, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.268218.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Horner, Daniel. "Isolated distal deep vein thrombosis in symptomatic ambulatory patients : a prospective data analysis and therapeutic feasibility study." Thesis, University of Manchester, 2013. https://www.research.manchester.ac.uk/portal/en/theses/isolated-distal-deep-vein-thrombosis-in-symptomatic-ambulatory-patients-a-prospective-data-analysis-and-therapeutic-feasibility-study(02979c49-ec26-4099-b0f8-3da2acbf0672).html.

Full text
Abstract:
Isolated distal deep vein thrombosis (IDDVT) is a condition recently suggested to be a different entity to that of proximal disease. There is currently little evidence defining the clinical importance of detection and treatment. International guidelines vary regarding management advice.An observational cohort study, prospective service evaluation and pilot randomised controlled trial were performed within a United Kingdom ambulatory thrombosis service. This project aimed to describe the burden of disease and explore three poorly researched aspects of IDDVT assessment and management: whole-leg compression ultrasound (CUS) performed by non-physicians within an ambulatory framework as a principal diagnostic modality; clinical presentation data and risk profile in comparison to that of proximal disease; the feasibility of further interventional randomised research and the risk/benefit profile of therapeutic anticoagulation.Within this ambulatory cohort, IDDVT accounted for 49.7% of acute thrombosis and differed significantly to proximal disease regarding provocation and symptomatology at clinical presentation. A negative whole-leg CUS excluded deep vein thrombosis with an adverse event rate (diagnosis of symptomatic venous thromboembolism during the 3 month follow up period) of 0.47% (95% CI 0.08 to 2.62). Future interventional research was proved feasible within an ambulatory setting.The randomised controlled trial conducted within this project is the largest to date comparing therapeutic anticoagulation against conservative strategy for the management of acute IDDVT. Patients allocated to therapeutic anticoagulation had significantly less overall propagation of thrombus (Absolute risk reduction [ARR] 25.7%, 95% Confidence interval 5.9 to 44.3 p<0.01), less short-term symptomatic progression (ARR 16.7%, 95% CI 2.6 to 32.1 p=0.05) and a result trending towards significance for reduction in serious thromboembolic complications (ARR 11.4%, 95% CI -1.5 to 26.7 p=0.11).IDDVT is a condition of equal prevalence to proximal venous thrombosis, which varies significantly regarding risk profile and clinical presentation. Using a single whole leg CUS reported by a non-physician within an emergency department pathway is associated with a low adverse event rate. This contemporary data also suggests that therapeutic anticoagulation is beneficial for reduction of short-term complications in IDDVT. The risk of false positive diagnosis and excess anticoagulation remains.This data can inform and direct future design of adequately powered randomised studies, in order to attempt external validation of these findings.
APA, Harvard, Vancouver, ISO, and other styles
8

Pazzini, Carla. "Preparação e caracterização de nanoparticulas com heparina e sua avaliação em modelo animal de trombose venosa." [s.n.], 2010. http://repositorio.unicamp.br/jspui/handle/REPOSIP/310166.

Full text
Abstract:
Orientadores: Joyce Maria Annichino-Bizacchi, Nelci Fenalti Hoher
Dissertação (mestrado) - Universidade Estadual de Campinas. Faculdade de Ciencias Medicas
Made available in DSpace on 2018-08-15T09:49:31Z (GMT). No. of bitstreams: 1 Pazzini_Carla_M.pdf: 2143259 bytes, checksum: b3ff6eb2527b691a4021526983ef2aeb (MD5) Previous issue date: 2010
Resumo: A heparina é um anticoagulante amplamente empregado no tratamento e profilaxia da trombose venosa profunda (TVP). Algumas limitações do seu uso são o custo e a via de administração, endovenosa ou subcutânea, às vezes em doses repetidas em 24 horas. Assim, o desenvolvimento de um produto que possa ser administrado por via subcutânea em um menor número de aplicações ou por via oral, torna-se um importante desafio, e de grande aplicabilidade clínica. A utilização de um sistema de liberação sustentada de fármacos pode vir ao encontro desse objetivo, pois permite que o agente seja protegido e liberado gradativamente. Este projeto consistiu na preparação e caracterização de nanopartículas biodegradáveis de poli (e-caprolactona) (PCL) como carreador de heparina de baixo peso molecular, e avaliação de sua atividade anticoagulante e antitrombótica in vivo. As nanopartículas foram preparadas pelo método de dupla emulsão a/o/a e evaporação de solvente. A caracterização das nanopartículas foi realizada por microscopia eletrônica de varredura (MEV), observando-se nanopartículas esféricas e homogêneas. O diâmetro médio das nanopartículas foi de 269 ± 36 nm e o potencial zeta foi de -1,20 ± 1,93 mV, indicando que as mesmas apresentam carga negativa. A eficiência de encapsulação, analisada pelo método Azure II, foi de 80 ± 2,3%. A liberação da heparina in vitro, avaliada pelo método de Azure II, no período de 24 horas foi de 4 ± 1,8%. Após a adição da esterase houve um aumento para 10 ± 1,9% na liberação de heparina, provavelmente pela aceleração da degradação das partículas pela enzima. A liberação in vivo da heparina encapsulada, após aplicação subcutânea em ratos, foi avaliada pela atividade anti-Xa plasmática através do método colorimétrico, e os resultados foram comparados aos obtidos com heparina livre. A dose de heparina encapsulada teve que ser 5 vezes maior que a dose de heparina livre. A heparina encapsulada em nanopartículas apresentou uma liberação sustentada por até 12 horas, por um período significativamente mais prolongado (P<0,01), mas com menor atividade anti-Xa. Esses dados sugerem que as nanopartículas podem permitir que a heparina seja liberada de uma forma mais gradual, e mesmo em dose mais elevada, não parece estar associada a um risco de atividade acima da faixa terapêutica. Quando se comparou a atividade anti-Xa obtida pela injeção subcutânea de nanopartículas com heparina em doses diversas, 800 UI/Kg e 1000 UI/Kg, ficou demonstrado que o efeito e o tempo de ação dependem da dose aplicada. Para avaliação da ação antitrombótica foi padronizado o modelo de TVP por estase em ratos. As doses de nanopartículas empregadas para a avaliação da ação antitrombótica foram calculadas pela atividade anti-Xa semelhante à obtida com a heparina livre, de 0,3 a 0,7 UI/mL. A heparina livre ou encapsulada em nanopartículas foi aplicada em uma única dose, por via subcutânea. Os resultados mostraram que houve diminuição significativa do trombo formado com a utilização de heparina livre, em comparação ao grupo controle (P=0,004). Praticamente não houve a formação de trombose venosa em nenhum dos ratos que receberam a heparina encapsulada em nanopartículas, com uma diferença significativa tanto em relação ao grupo controle (P<0,001) como ao grupo com heparina livre (P<0,001). Em resumo, o método de dupla emulsão a/o/a mostrou-se um método eficiente para o encapsulamento de heparina, proporcionando a obtenção de nanopartículas esféricas e com alta eficiência de encapsulação. Pelos estudos in vivo, a heparina encapsulada não liofilizada mostrou uma liberação sustentada, por um período superior ao obtido com a heparina livre, e com excelente ação antitrombótica. Caso esses resultados se confirmem através da continuidade deste estudo, a utilização de heparina encapsulada em nanopartículas na prática clínica poderá ser uma realidade com grandes vantagens para o paciente.
Abstract: Heparin is an anticoagulant widely used in the treatment and prophylaxis of deep vein thrombosis (DVT). Some limitations of its use is the cost and route of administration, intravenous or subcutaneous, sometimes in repeated doses in 24 hours. Thus, the development of a product that can be administered subcutaneously in a smaller number of applications or orally becomes a major challenge, with interesting clinical applications. The use of a system for sustained release of drugs can come to meeting that goal, because it allows the agent to be protected and released gradually. This project consisted of the preparation and characterization of biodegradable nanoparticles of poly (e-caprolactone) (PCL) as a carrier of heparin of low molecular weight, and its evaluation of anticoagulant and antithrombotic activity in vivo. The nanoparticles were prepared by the method of double emulsion w/o/w and evaporation of solvent. The characterization of nanoparticles was performed by scanning electron microscopy (SEM), which showed homogeneous spherical nanoparticles. The average diameter of nanoparticles was 269±36 nm and zeta potential was -1.20±1.93 mV, indicating negative charge. The encapsulation efficiency, assayed by Azure II, was 80±2.3%. The release of heparin in vitro, at the 24-hour period was 4±1.8%. After the addition of esterase the release of heparin was increased to 10±1.9%, probably by accelerating the degradation of particles by the enzyme. The in vivo release of encapsulated heparin after subcutaneous administration in rats, was assessed by anti-Xa plasma activity and the results were compared with free heparin. The dose of heparin encapsulated had to be 5 times the dose of heparin free. Heparin-encapsulated nanoparticles showed a sustained release for up to 12 hours for a period significantly longer (P<0.01), but with lower anti-Xa activity. These data suggest that nanoparticles may allow heparin to be released in a more gradual, but with lower activity. When comparing the anti-Xa activity obtained by subcutaneous injection of nanoparticles with different doses of heparin, 800 IU/kg and 1000 IU/kg, demonstrated that the effect and duration of action depends on the dose applied. To evaluate the antithrombotic action of nanoparticles with heparin a model of DVT by stasis in rats was used. The doses of nanoparticles used for the evaluation of antithrombotic action were calculated by anti-Xa activity similar to that obtained with free heparin, 0.3 to 0.7 IU/mL. Heparin free or encapsulated in nanoparticles was applied in a single dose subcutaneously. The results showed a significant decrease of thrombus formed with the use of free heparin, compared with the control group (P=0.004). There were virtually no formation of venous thrombosis in any of the rats that received heparin encapsulated in nanoparticles, with a significant difference both in the control group (P<0.001) and the group with free heparin (P<0.001). In summary, the method of double emulsion w/o/w proved an efficient method for the encapsulation of heparin, providing spherical homogeneous nanoparticles with high encapsulation efficiency. For in vivo studies, heparin encapsulated showed a sustained release for a period greater than that of free heparin, and with excellent antithrombotic action. If these results are confirmed by the continuity of this study, the use of heparin encapsulated in nanoparticles in clinical practice can be of great benefits for the patient.
Mestrado
Medicina Experimental
Mestre em Fisiopatologia Médica
APA, Harvard, Vancouver, ISO, and other styles
9

Andia, Kohnenkampf Marcelo. "Venous thrombosis : formation, evolution and resolution imaging using non-invasive MRI techniques." Thesis, King's College London (University of London), 2012. https://kclpure.kcl.ac.uk/portal/en/theses/venous-thrombosis-formation-evolution-and-resolution-imaging-using-noninvasive-mri-techniques(99e7c5ac-77eb-4d0e-aad7-c90aa4202c79).html.

Full text
Abstract:
Deep venous thrombosis (DVT) remains a major health problem. Although thrombolytic therapies are effective in recanalising the veins, restoring blood flow, preventing pulmonary embolism and post-thrombotic complications, there is still no consensus on the selection criteria for this invasive treatment. Experimental data suggest that thrombus rich in fibrin has better response to thrombolysis than red cell rich (acute phase) or collagen rich (chronic) thrombus. Thus, there is a need for a diagnostic technique that provides better information on the stage of thrombus organization in-vivo and allows identification of thrombus suitable for thrombolysis. Current imaging modalities for the diagnosis of DVT do not provide information on the biological stage of thrombus organization. Contrast venography is still considered the gold standard for the diagnosis of DVT, even though thrombi are not clearly visualized and they are indirectly detected due to alterations in blood flow. The aim of this thesis was to develop and validate new imaging methodology for the better evaluation of DVT using Magnetic Resonance Imaging (MRI). The first aim was to investigate the potential of non-contrast enhanced MRI sequences including T1 mapping, T2* mapping, Magnetization Transfer Contrast (MTC), and Apparent Diffusion Coefficients (ADC) maps for the detection of thrombus in a murine model of deep venous thrombosis. The second aim was to investigate the merit of a fibrin and macrophage specific MR contrast agent for the detection of DVT. Both fibrin and macrophages play a major role in thrombus organization. The third aim was to investigate the merits of the fibrin binding contrast agent for the guidance of thrombolysis. We also developed two new non-contrast enhanced venous spin labelling approaches in order to obtain venograms without the need of a contrast agent and thereby to improve non-invasive DVT diagnosis using MRI. In conclusion, this thesis proposes a new imaging methodology for the accurate staging of thrombus organization and the successfully detection of thrombus amenable for thrombolysis in a murine model of DVT. The translation of this technique into the clinic should have great potential to change clinical evaluation and treatment of patients with DVT.
APA, Harvard, Vancouver, ISO, and other styles
10

Vossen, Carolina Y. "Genetic risk factors for venous thrombosis : key players or minor risk modifiers ? /." [S.l. : s.n], 2005. http://catalogue.bnf.fr/ark:/12148/cb402235083.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Venous thrombosis"

1

Ogston, Derek. Venous thrombosis: Causation and prediction. Chichester: Wiley, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

V, Caso, Agnelli Giancarlo, and Paciaroni M, eds. Handbook on cerebral venous thrombosis. Basel: Karger, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

1932-, Dalen James E., ed. Venous thromboembolism. New York: Marcel Dekker, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Malone, P. Colm, and Paul S. Agutter. The Aetiology of Deep Venous Thrombosis. Dordrecht: Springer Netherlands, 2008. http://dx.doi.org/10.1007/978-1-4020-6650-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Z, Goldhaber Samuel, ed. Pulmonary embolism and deep venous thrombosis. Philadelphia: Saunders, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

National Institutes of Health (U.S.). Office of Medical Applications of Research., ed. Prevention of venous thrombosis and pulmonary embolism. [Bethesda, MD: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, Office of Medical Applications of Research], 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

1935-, Hirsh Jack, ed. Venous thrombosis and pulmonary embolism: Diagnostic methods. Edinburgh: Churchill Livingstone, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Prevention of venous thromboembolism. London: Med-Orion, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bergan, John J. Management of venous disorders. Georgetown, Tex., U.S.A: Landes Bioscience, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hirsh, Jack. Venous thromboembolism: Guide to management. Mississauga, Ont: Du Pont Pharmaceuticals, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Venous thrombosis"

1

Yale, Steven H., Halil Tekiner, Joseph J. Mazza, Eileen S. Yale, and Ryan C. Yale. "Venous Thrombosis: Cerebral Venous Thrombosis." In Cardiovascular Eponymic Signs, 385–90. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-67596-7_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lasjaunias, Pierre. "Venous Thrombosis." In Vascular Diseases in Neonates, Infants and Children, 419–44. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-662-10740-9_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hughes, Graham, and Shirish Sangle. "Venous Thrombosis." In Hughes Syndrome: The Antiphospholipid Syndrome, 13–17. London: Springer London, 2011. http://dx.doi.org/10.1007/978-0-85729-739-6_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Roth, Elliot J. "Venous Thrombosis." In Encyclopedia of Clinical Neuropsychology, 3566. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-57111-9_2212.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Roth, Elliot. "Venous Thrombosis." In Encyclopedia of Clinical Neuropsychology, 1–2. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-56782-2_2212-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Knight, L. C., and A. H. Maurer. "Venous thrombosis." In Clinical Nuclear Medicine, 203–14. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4899-3356-0_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hach, Wolfgang, and Viola Hach-Wunderle. "Venous Thrombosis." In Phlebography and Sonography of the Veins, 145–72. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60330-3_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Roth, Elliot J. "Venous Thrombosis." In Encyclopedia of Clinical Neuropsychology, 2596. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-0-387-79948-3_2212.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Littig, Ingrid Aguiar, and Antônio José da Rocha. "Venous Thrombosis." In Critical Findings in Neuroradiology, 93–102. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-27987-9_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Qinming, Zhang. "Thrombosis." In Totally Implantable Venous Access Devices, 173–81. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2373-4_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Venous thrombosis"

1

Bazil, M., J. Scaggiante, J. Mocco, and C. Kellner. "E-265 Thrombosis of two or more venous sinuses in cerebral venous thrombosis." In SNIS 19th Annual Meeting Abstracts. BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd., 2022. http://dx.doi.org/10.1136/neurintsurg-2022-snis.376.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lowe, O. DG. "RHEOLOGY AND VENOUS THROMBOEMBOLISM." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643990.

Full text
Abstract:
Changes in the composition of the blood, venous stasis, and interaction of the blood with the vessel wall (Virchow's triad) all have rheological aspects which may promote venous thrombogenesis.Blood composition and rheology. Increasing levels of venous haematocrit and fibrinogen increase bulk blood viscosity, especially at low shear rates such as are encountered in veins, when red cell aggregation occurs. Static blood requires a minimum shear stress for flow (yield stress), which is also strongly dependent on haematocrit and fibrinogen levels. Increases in haematocrit and fibrinogen also promote platelet adhesion and aggregation. Polycythaemia carries an increased risk of venous thromboembolism, which can be reduced by lowering the haematocrit; conversely, anaemic patients (renal failure, pernicious anaemia) have a subnormal prevalence of pulmonary embolism at autopsy. Increased preoperative levels of haematocrit, fibrinogen and blood viscosity predicted postoperative deep vein thrombosis in some studies, but not in others: they have complex relationships to other risk factors and illnesses. Postoperative changes in haematocrit, fibrinogen and blood viscosity may also be relevant to thrombogenesis, as may haemoconcentration in leg veins.Venous flow disturbance and rheology. The flow behaviour of particles and cells in venous valve pockets has been studied by Karino: particles and cells were observed to leave mainstream flow and circulate in paired vortices in low-shear areas within the valve pockets. A cell-poor hypoxic area at the apex of the valve pocket may favour thrombogenesis. Valve pockets might therefore act as in vivo aggregometers, with optimal conditions for activated cells or coagulation products to promote platelet and red cell aggregation, which might be facilitated by increases in haematocrit or fibrinogen. Sevitt has observed cellular aggregates in valve pockets at autopsy, which might act as a nidus for thrombus initiation. Successive layers of thrombus will disturb flow steamlines, as well as generating procoagulant activity: hence a series of "aggregometers" might result in successive bursts of thrombosis and the layered structure of venous thrombi observed by Sevitt. Variations in haematocrit, fibrinogen and red cell aggregation may influence stasis of blood following venous occlusion by thrombus, and hence affect thrombotic extension; they may also influence residual lung perfusion following pulmonary embolism.Therapeutic aspects of rheology. Leg stockings and other physical methods of preventing deep vein thrombosis may improve flow disturbance in valve pockets, as well as in axial veins. The efficacy of perioperative dextran in prevention of venous thromboembolism may partly reflect haemodilution and its rheological consequences. Likewise, postoperative defibrination with ancrod reduced the incidence and extent of deep vein thrombosis after hip surgery, which may partly reflect reductions in plasma viscosity and red cell aggregation. Defibrination with ancrod reduced the haemodynamic disturbance, and the mortality, of experimental pulmonary embolism in dogs, possibly by increasing residual perfusion.. Similarly, improved perfusion after thrombolytic therapy of pulmonary embolism in man may reflect the rheological consequences of fibrinogen depletion, as well as thrombolysis.
APA, Harvard, Vancouver, ISO, and other styles
3

Neuhoff, A., L. Jennwein, I. Voigt, F. Louwen, and D. Brüggmann. "Maternal mortality in venous sinus thrombosis." In 62. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe – DGGG'18. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1671550.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Saidani, Amal, Nesrine Kallel, Rym Khemekhem, Nadia Moussa, Rahma Gargouri, Wajdi Feki, and Samy Kammoun. "Cerebral venous thrombosis in Covid-19." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa3889.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Turple, A. G. G., M. N. Levin, J. Hirish, C. J. Carter, R. M. Jay, P. J. Powers, M. Andrew, H. N. Magnani, R. D. Hull, and M. Gent. "A DOUBLE BLIND RANDOMIZED TRIAL OF ORG 10172 LOW MOLECULAR WEIGHT HEPARINOID IN THE PREVENTION OF DEEP VEIN THROMBOSIS IN PATIENTS WITH THROMBOTIC STROKE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643239.

Full text
Abstract:
The optimal method of venous thrombosis prophylaxis in patients with stroke is uncertain. ORG 10172 is a low molecular weight heparinoid consisting principally of heparan and dermatan sulphates. In animal studies, ORG 10172 is as effective as unfractionated heparin in preventing venous thrombosis but produces less bleeding. There have been a limited number of descriptive studies on its use in humans, but to date randomized efficacy trials of ORG 10172 in the prevention of venous thrombosis have not been reported. A double blind randomized trial was carried out to compare ORG 10172 with placebo in the prevention of deep vein thrombosis in patients with thrombotic stroke. Seventy-five patients were randomized to receive ORG 10172 (50 patients) in a loading dose of 1,000 anti-Xa units intravenously followed by 750 anti-Xa units subcutaneously 12 hourly or placebo (25 patients). Prophylaxis was commenced within 7 days of stroke onset, continued for 14 days or until discharge from hospital, if earlier. Venous thrombosis surveillance was carried out with 125-1 fibrinogen leg scanning and impedance plethysmography. Venous thrombosis was confirmed by venography which occurred in 2 of 50 (4%) in the ORG 10172 group and 7 of 25 (28%) in the placebo group (p=0.005). The corresponding rates for proximal vein thrombosis were 0% and 16%, respectively (p=0.01). There was one major haemorrhage in the treated group and one minor haemorrhage in the placebo group. The anti-factor Xa levels (units/ml; mean ± SE) gradually rose from 0.18 ± 0.001 and 0.06 ± 0.01 six and 12 hours after injection on the first day to 0.24 ± 0.02 and 0.12 ± 0.01 after 11 days treatment. The results of this study indicate that ORG 10172 heparinoid is effective prophylaxis against deep vein thrombosis in patients with acute thrombotic stroke.
APA, Harvard, Vancouver, ISO, and other styles
6

Lavenne-Pardonge, E., C. Col-De Beys, and M. Moriau. "INTEREST OF THE RATIO OF INCREASE OF (β-THROMBOGLOBULIN (Δ+/βTG) AND OF FIBRINOPEPTIDE A (Δ+ FPA) FOR DIAGNOSIS AND TREATMENT OF THR0MB0-EMB0LIC DISEASES." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643050.

Full text
Abstract:
The interest of release of TG and FPA for the diagnosis and treatment of prethrombotic and thrombotic disorders is well knownThe ratio of increase of these two parameters (Δ+βTG/+ FPA) seems to bring some additional informations.This ratio, normally about 1, increases in isolated or preponderant platelet activation and decreases when platelet activation plays a minor role than the plasmatic factors. A more logical choice of therapeutics and a better control of its effectiveness are so possible.This study includes 91 cases of established thrombosis (20 arterial and 71 venous) and 272 cases of prethrombotic disorders (58 Raynaud syndromes, 54 cases of venous insufficiency, 60 of hip prosthesis, 40 of coronary by-pass, 60 of valvular replacement). The ratio + TG/ + FPA was calculated before, during and after efficacious or inefficacious treatment. In the cases of established thrombosis, our results confirm the leading role of platelets in the development of arterial thrombosis. The cases of venous thrombosis may be divided in two groups : simple venous thrombosis when the plasmatic factors play a leading role and complicated or recurrent venous thrombosis where the platelets play an equivalent or even a greater role.In the cases of prethrombotic states, the role of the platelets which is important on the arterial side is generally far from negligeable on the venous side. In cases of valvular replacement or of coronary by-pass the modification of the ratio lead us very frequently to modify our prophylactic therapeutics
APA, Harvard, Vancouver, ISO, and other styles
7

Lima, Iana Campinho Braga de Araújo, Lavínia Flávia Xavier de Souza, Clara Wilma Fernandes Rosendo, Letícia de Freitas Barradas, Emerson Kennedy Ribeiro de Andrade Filho, Pedro Vilar de Oliveira Villarim, Gianluca Gomes Siebra, Ródio Luis Brandão Câmara, and Moisés Felipe da Costa Fernandes. "Cerebral venous thrombosis simulating cerebral arterial thrombosis: Late complication of COVID-19?" In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.345.

Full text
Abstract:
Context: Brain venous thrombosis (BVT) is uncommon and usually has a different clinic and treatment from cerebral arterial thrombosis. In this context, COVID-19 correlates with thrombogenesis with varied clinical repercussions. This report describes an unusual BVT case as a possible late complication of COVID-19. Case report: Male, 68 years old, athlete and healthy. April/2020: COVID-19 mild symptoms. February/2021: in road-running, he fell due to sudden left hemiparesis. Upon hospital admission: contacting, persistent headache. A week after, low level of consciousness and coma, when underwent right hemicraniectomy. Remains hospitalized. On examination: weak gestural communication, tracheostomy, enteral tube feeding, voluntary blinking. Maintains neutral cervical posture, masticatory automatisms, photoreactive isocoria, generalized rigidity, decorticated right hemiparesis, left hemiplegia. On imaging: hemorrhagic infarction on the right and mass effect due to obstruction of the Basal Rosenthal and Labbé veins and transverse sinus on the right, with venous blood flow in the rest of the hemisphere diverted to the ipsilateral internal jugular vein, by anastomotic veins of the occipital foramen and suboccipital venous plexus. Obstructed left internal jugular vein, with venous collateral flow from the left hemisphere via posterior intercavernous sinus and basilar plexus to the right internal jugular vein. Conclusions: To diagnose the venous etiology that resembled segmental occlusion of the right middle cerebral artery, CT angiography was required. Late evolution of COVID-19 has been identified by the persistence of symptoms for months. Although physical activity and possible dehydration may have contributed to BVT, a prothrombotic state correlated to COVID-19 cannot be discarded.
APA, Harvard, Vancouver, ISO, and other styles
8

Hach-Wunderle, V., R. Walter-Fincke, H. K. Beck, and I. Scharrer. "FAMILY STUDIES OF PATIENTS WITH RECURRENT VENOUS THROMBOSES AND INHERITED DISORDERS OF BLOOD COAGULATION OR FIBRINOLYSIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643045.

Full text
Abstract:
Several defects of the coagulation and/or fibrinolytic system have been found to be associated with venous thromboembolism. In young patients with recurrent thromboses or a positive family history, an inherited disorder should be excluded535 young patients with venous thromboses, phlebitis and/or pulmonary embolism were investigated from 1980 until 1986. The first thrombotic event had occurred at an age of less than 45 years.An inborn disorder of the blood coagulation or fibrinolytic system was found in 18 families. Most of them (n=13/18) had a positive family history. In all families either thromboses had occurred in at least one member (n=12/18) and/or the defect could be detected in one of them (n=12/18)Most often we found a deficiency of antithfombin III (n=6). A deficiency of protein C (type I) was detected in 3 and a deficiency of protein S in 5 families. In one patient a combined deficiency of anti thrombin III, protein C and protein S was found. Extensive family studies revealed a deficiency of antithrombin III in the grandmother of the patient, who suffered from arterial thrombosis. A deficiency of plasminogen and an abnormal plasminogen molecule were detected in 2 other families. Defective release of t-PA could be demonstrated in 3 members of one investigated family up to nowSeme family members with either defects of protein C, protein S or plasminogen as well as a defective release of t-PA lack thrombotic events. Furthermore thromboses of mesenteric veins occurred in 2 of 6 patients with anti thrombin III deficiency and in 1 of 5 patients with protein S deficiency. Superficial vein thromboses were mainly found in patients with protein C- or protein S-deficiency
APA, Harvard, Vancouver, ISO, and other styles
9

Pereira, J., M. Hewicker-Trautwein, M. Depka Prondzinski, and R. Mischke. "Central venous catheter associated thrombosis in dogs." In 27. Jahrestagung der FG „Innere Medizin und klinische Labordiagnostik“ der DVG (InnLab), 2./3. Februar 2019 in München – Teil 2. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1679119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pereira, JM, M. Hewicker-Trautwein, K. Rohn, M. von Depka Prondzinski, and R. Mischke. "Central venous catheter induced thrombosis in dogs." In 29. Jahrestagung der FG „Innere Medizin und klinische Labordiagnostik“ der DVG (InnLab) – Teil 2: Poster. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1723884.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Venous thrombosis"

1

Shi, Guoxin, and Wen Zhao. Risk factors for deep venous thrombosis in patients with stroke: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0045.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Akbari, Ardalan. Luc’s Abscess: First Reported Case with Coexisting Intracranial Abscess and/or Venous Sinus Thrombosis. Science Repository OÜ, August 2018. http://dx.doi.org/10.31487/j.scr.2018.03.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

LI, Weihui LI, Feng Xu, Weijing Fan, Guobin Liu, Lei Xu, Xvhong Wang, Huimin Lu, and Yuanxiang LI. Xueshuantong injection in treating Deep Venous Thrombosis: a systematic review and experimental sequential analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2020. http://dx.doi.org/10.37766/inplasy2020.12.0117.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Xiong, Yuchen, Weiwei Wu, and Shanzi Yu. Different spine tumor pathology and risk of venous thrombosis : systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2023. http://dx.doi.org/10.37766/inplasy2023.3.0121.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hatzfeld, Jennifer, Maria Kohler, and Susan Dukes. FDG20100017H Incidence of Venous Thomboembolism 9VTE) and Effect of Thrombosis Prophylaxis Guidelines in Patients Transported Aeromedically. Fort Belvoir, VA: Defense Technical Information Center, May 2014. http://dx.doi.org/10.21236/ada608673.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

A, Bengolea, Chamorro F, Ozon N, Catalano HN, and Izcovich A. Effectiveness and safety of utilizing imaging techniques to guide treatment in patients with venous thromboembolism. Epistemonikos Interactive Evidence Synthesis, January 2023. http://dx.doi.org/10.30846/ies.2b03926263.v1.

Full text
Abstract:
Objective The objective of this systematic review is to perform a comprehensive evaluation of the efficacy and safety of the use of imaging to determine the duration of anticoagulant treatment in patients with thrombosis of any cause (idiopathic, resolved secondary or chronic) who have completed a period of 3 to 6 months of oral anticoagulant treatment. Methods In order to identify randomized clinical trials that evaluate our question of interest, we performed exhaustive searches in Epistemonikos and PubMed, from the date of creation of each source until February 2024. Additionally, we considered additional sources to identify trials that may not have been identified through electronic search. Two reviewers independently selected included studies, extracted data, and assessed risk of bias. We performed a quantitative synthesis (meta-analysis) and prepared summary tables of findings as recommended by the GRADE group. The results of this review were presented to a team of clinical experts from the medical clinic service of the German Hospital of Buenos Aires, who analyzed and made judgments for each of the proposed criteria within the framework of the evidence for the decision. After making judgments for each criterion, the experts formulated the clinical recommendation for the problem of interest. Result Through the search strategy, 514 references were identified and examined by title and abstract. Of these, 17 references were included for full-text evaluation. Finally, 2 randomized clinical trials were included. The evidence on the use of CT or venous Doppler to determine the duration of anticoagulation in patients with thromboembolic events of any type is very uncertain. The evidence on the use of tomography or venous Doppler to determine the duration of anticoagulation in patients with idiopathic thromboembolic events secondary to transient and/or chronic risk factors (patients with cancer) is very uncertain. Clinical recommendation The medical clinic service of the German Hospital [link_recommendation|recommendation](does not recommend using image-guided strategies to suspend anticoagulant treatment in patients with thromboembolisms) (CONDITIONAL RECOMMENDATION AGAINST, VERY LOW CERTAINTY IN THE EVIDENCE). Conclusions In this systematic review, we explored the usefulness of using imaging (tomography or venous Doppler) to determine the continuity of treatment with oral anticoagulants in patients with venous thrombosis. However, the evidence derived from the included studies has very low certainty.
APA, Harvard, Vancouver, ISO, and other styles
7

A, Bengolea, Chamorro F, Ozon N, Catalano HN, and Izcovich A. Effectiveness and safety of utilizing imaging techniques to guide treatment in patients with venous thromboembolism. Epistemonikos Interactive Evidence Synthesis, April 2024. http://dx.doi.org/10.30846/ies.2b03926263.

Full text
Abstract:
Objective The objective of this systematic review is to perform a comprehensive evaluation of the efficacy and safety of the use of imaging to determine the duration of anticoagulant treatment in patients with thrombosis of any cause (idiopathic, resolved secondary or chronic) who have completed a period of 3 to 6 months of oral anticoagulant treatment. Methods In order to identify randomized clinical trials that evaluate our question of interest, we performed exhaustive searches in Epistemonikos and PubMed, from the date of creation of each source until February 2024. Additionally, we considered additional sources to identify trials that may not have been identified through electronic search. Two reviewers independently selected included studies, extracted data, and assessed risk of bias. We performed a quantitative synthesis (meta-analysis) and prepared summary tables of findings as recommended by the GRADE group. The results of this review were presented to a team of clinical experts from the medical clinic service of the German Hospital of Buenos Aires, who analyzed and made judgments for each of the proposed criteria within the framework of the evidence for the decision. After making judgments for each criterion, the experts formulated the clinical recommendation for the problem of interest. Result Through the search strategy, 514 references were identified and examined by title and abstract. Of these, 17 references were included for full-text evaluation. Finally, 2 randomized clinical trials were included. The evidence on the use of CT or venous Doppler to determine the duration of anticoagulation in patients with thromboembolic events of any type is very uncertain. The evidence on the use of tomography or venous Doppler to determine the duration of anticoagulation in patients with idiopathic thromboembolic events secondary to transient and/or chronic risk factors (patients with cancer) is very uncertain. Clinical recommendation The medical clinic service of the German Hospital [link_recommendation|recommendation](does not recommend using image-guided strategies to suspend anticoagulant treatment in patients with thromboembolisms) (CONDITIONAL RECOMMENDATION AGAINST, VERY LOW CERTAINTY IN THE EVIDENCE). Conclusions In this systematic review, we explored the usefulness of using imaging (tomography or venous Doppler) to determine the continuity of treatment with oral anticoagulants in patients with venous thrombosis. However, the evidence derived from the included studies has very low certainty.
APA, Harvard, Vancouver, ISO, and other styles
8

Cheng, Fangqun, Biyun Ye, Ying Tang, Zhuo Xiao, Dan Liu, Ke Wang, Peiyu Cheng, and Jingping Zhang. Risk factors for deep vein thrombosis in patients with cerebral hemorrhage: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0068.

Full text
Abstract:
Review question / Objective: To identify the risk factors of deep venous thrombosis in patients with cerebral hemorrhage. Eligibility criteria: Inclusion criteria: ①Comply with the “Guidelines for diagnosis of cerebral hemorrhage in China”[7] or “Guidelines for the management of spontaneous intracerebral hemorrhage in the United States”[37], or be diagnosed as ICH in combination with brain CT, MRI, and cerebral angiography; ②Age ≥18 years old; ③Ultrasonography or color polygraph Pler ultrasonography confirmed DVT; ④ The study type was cohort study or case-control study; ⑤ Newcastle-Ottawa Scale (NOS) [8] score ≥ 6 points; ⑥ The language was limited to Chinese and English. Exclusion criteria: ① Repeated publications; ② Studies without full text, incomplete information, or data extraction impossible.
APA, Harvard, Vancouver, ISO, and other styles
9

Du, Yuqing, Huimin Lu, Yaoqing Sun, Weian Yuan, Renyan Huang, Xuhong Wang, Guobin Liu, and Weijing Fan. Systematic review and meta-analysis of the efficacy and safety of Panax notoginseng saponins in the prevention of lower-extremity deep venous thrombosis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2023. http://dx.doi.org/10.37766/inplasy2023.3.0032.

Full text
Abstract:
Review question / Objective: P: Participants must be individuals diagnosed with LEDVT. I: Panax Notoginseng Saponions (PNS) alone or PNS combined with routine western medicine treatment; C: Western medicine. O: The Incidence of LEDVT. Condition being studied: The lower-extremity deep vein thrombosis (LEDVT) is a condition that is common in postoperative and intensive care patients. It is caused by impaired venous reflux, endothelial dysfunction and ahypercoagulability. Eligibility criteria: All randomized controlled trials (RCTs) exploring the clinical outcomes of PNS alone or PNS combined with western medicine versus western medicine with LEDVTwere includedAll randomized controlled trials (RCTs) exploring the clinical outcomes of Zishen Yutai Pill plus western medicine versus western medicine with TM in woman were included.
APA, Harvard, Vancouver, ISO, and other styles
10

hou, xianbing, dandan chen, tongfei cheng, dan wang, xiaojun dai, yao wang, bixian cui, et al. Bleeding risk of anticoagulant therapy in patients with advanced cancer in palliative care settings：a protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0064.

Full text
Abstract:
Review question / Objective: The systematic review aim to provide synthesised and appraised evidence to assess the bleeding risk of anticoagulant therapy in patients with advanced cancer in palliative care settings. Condition being studied: Cancer is a recognized risk factor for venous thromboembolism (VTE). The main forms of thromboembolic disease include pulmonary embolism (PE) and deep vein thrombosis (DVT). Given their diagnosis and often poor physical status, patients with advanced cancer are at particularly high risk of developing VTE, resulting in reduced activity levels or even immobility. The exact incidence and prevalence of VTE in the population of cancer patients receiving hospice or palliative care has not been well investigated and few reports are available. Clinical studies have not yet determined whether such patients benefit from anticoagulant therapy and whether there is an increased risk of bleeding and death.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Venous thrombosis' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography